The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Licensing and acquisitions for emerging therapeutic companies worldwide in 2015 and 2016 (in billion U.S. dollars)
Global licensing and acquisitions for emerging therapeutic companies 2015-2016
This graph shows worldwide licensing and acquisitions for emerging therapeutic companies for the years 2015 and 2016, in billion U.S. dollars. In 2015, global market-stage acquisitions totaled nearly ** million U.S. dollars.
Log in or register to access precise data.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Global licensing and acquisitions for emerging therapeutic companies 2010-2019
- Basic Statistic Worldwide therapeutic licensing and acquisition deals share 2009-2018 by disease type
- Premium Statistic U.S. number of IPOs for neurology companies 2006-2024
- Basic Statistic U.S. venture investments in infectious disease companies 2006-2023
- Basic Statistic U.S. oncology company IPOs 2006-2023
- Premium Statistic Factors impacting valuation of biopharma companies per executives 2020
- Basic Statistic Impact of U.S. biopharmaceutical industry on employment 2022
- Basic Statistic Biopharmaceutical industry impact on labor income U.S. 2022
- Basic Statistic Biopharmaceutical industry impact on output U.S. 2022
- Basic Statistic Biopharmaceutical industry impact on added value U.S. 2022
About the region
10
- Basic Statistic Biotech company R&D expenditure by country and by application 2014
- Basic Statistic Dedicated biotechnology companies by country and application 2014
- Premium Statistic Percentage return on R&D among large cap biopharma companies 2010-2020
- Basic Statistic Capital expenditures of Syneos Health 2013-2022
- Basic Statistic Orphan drug sales worldwide by therapy category 2030
- Basic Statistic Net income of Syneos Health 2013-2022
- Premium Statistic Market cap of select pharma companies with strong pipeline 2017
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Basic Statistic Select mid-size biotech firms by CEO compensation 2019
- Premium Statistic CAGR of pre-commercial biopharma pipeline by therapeutic worldwide 2010-2020
Selected statistics
10
- Basic Statistic U.S. investment for emerging therapeutic companies 2011-2023
- Basic Statistic Expected acquisitions of biopharma companies by type of asset 2021
- Premium Statistic Number of biopharmaceutical deals worldwide 2016-2020, by type
- Basic Statistic U.S. venture investments in oncology companies 2006-2023
- Basic Statistic Employment in California's life sciences industry in 2023-2024, by sector
- Premium Statistic Planned and actual healthcare and life sciences activity in 2020, by subsector
- Basic Statistic Expected valuation changes in healthcare and life sciences 2021, by subsector
- Premium Statistic Expected investment changes in biopharma and diagnostic lab services 2021
- Basic Statistic Total Lyme disease funding by National Institutes for Health 2015-2025
- Basic Statistic Californian organizations which received the highest funding from the NIH 2021
Other regions
10
- Basic Statistic Biotech company R&D expenditure selected countries by firm size 2014
- Basic Statistic Expected top life science startups in the U.S. 2024-2025
- Basic Statistic Physician office payment for biosimilars in Medicare Part B 2022
- Basic Statistic Changes in valuations of biopharma companies by extent 2020
- Basic Statistic Number of M&A healthcare deals in California and the U.S. in 2021, by sector
- Basic Statistic U.S. bioscience establishments totals 2019-2023
- Premium Statistic Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Premium Statistic Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
- Premium Statistic Major biologics to lose patent protection 2015-2020 by EU5 and U.S. revenue
- Premium Statistic Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
Related statistics
10
- Basic Statistic U.S. venture funding of therapeutic companies by disease type 2024
- Basic Statistic Share of life sciences employees in the UK in 2021, by region
- Basic Statistic U.S. venture investments in psychiatry companies 2006-2023
- Premium Statistic U.S. infectious disease company IPOs 2006-2023
- Basic Statistic Therapy fields in development pipelines in German biotech companies 2013
- Premium Statistic Active biopharmaceuticals ingredients in development Germany 2018
- Basic Statistic Healthcare deals quarterly U.S. 2017-2020, by value
- Basic Statistic Healthcare deals quarterly number U.S. 2019-2020, by industry
- Basic Statistic Largest biotech financing deals in the United States in Q4 2020, by company
- Basic Statistic Leading venture capital firms in U.S. healthcare in Q4 2020, by number of deals
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Biotechnology Innovation Organization. (June 1, 2017). Licensing and acquisitions for emerging therapeutic companies worldwide in 2015 and 2016 (in billion U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/596184/worldwide-licensing-acquisitions-emerging-therapeutic-companies/
Biotechnology Innovation Organization. "Licensing and acquisitions for emerging therapeutic companies worldwide in 2015 and 2016 (in billion U.S. dollars)." Chart. June 1, 2017. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/596184/worldwide-licensing-acquisitions-emerging-therapeutic-companies/
Biotechnology Innovation Organization. (2017). Licensing and acquisitions for emerging therapeutic companies worldwide in 2015 and 2016 (in billion U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/596184/worldwide-licensing-acquisitions-emerging-therapeutic-companies/
Biotechnology Innovation Organization. "Licensing and Acquisitions for Emerging Therapeutic Companies Worldwide in 2015 and 2016 (in Billion U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 1 Jun 2017, /statistics/596184/worldwide-licensing-acquisitions-emerging-therapeutic-companies/
Biotechnology Innovation Organization, Licensing and acquisitions for emerging therapeutic companies worldwide in 2015 and 2016 (in billion U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/596184/worldwide-licensing-acquisitions-emerging-therapeutic-companies/ (last visited July 29, 2026)
Licensing and acquisitions for emerging therapeutic companies worldwide in 2015 and 2016 (in billion U.S. dollars) [Graph], Biotechnology Innovation Organization, June 1, 2017. [Online]. Available: /statistics/596184/worldwide-licensing-acquisitions-emerging-therapeutic-companies/
Advertisement